Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ephedra sinica root, also known as Ma Huang gen, is derived from the plant *Ephedra sinica* (Ma Huang), a traditional Chinese medicinal herb. Unlike the stems of *Ephedra sinica*, which contain ephedrine alkaloids known for their stimulant and hypertensive effects and are banned in dietary supplements in the United States, the root does not contain appreciable amounts of these alkaloids. Instead, *Ephedra sinica root* is traditionally used for its hypotensive (blood pressure lowering) and antihydrotic (sweat-reducing) properties. Its active constituents include spermine alkaloids like ephedradines A-D, the flavonoid ephedrannin A, and feruloylhistamine, which are believed to contribute to its distinct pharmacological profile. The root's therapeutic actions are considered to be opposite to those of the stem.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ephedra sinica root.